Recordati: public disclosure compliance

Milan, 31st January 2012 – In accordance with the provisions of the “Instructions to the Rules for the markets organised and managed by Borsa Italiana S.p.A.” Recordati S.p.A. announces that the payment of the balance of the 2011 financial year dividend is planned for the 26th April 2012, with ex-dividend date on 23rd April 2012, while payment of the interim dividend for the 2012 financial year is planned for the 22nd November 2012, with ex-dividend date on 19th November 2012.

This press release has been issued by the Company for the sole purpose of compliance with Borsa Italiana S.P.A. regulations and is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar will be promptly notified to the market.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,800, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe.  A European field force of around 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati’s current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations.  Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases.  Consolidated revenue for 2010 was € 728.1 million, operating income was € 154.8 million and net income was € 108.6 million.

For further information:

Recordati website:  www.recordati.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company’s control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company’s activities and are not intended to indicate the advisability of administering any product in any particular instance.